Mpm Asset Management is an investment fund managing more than $182 billion ran by Christopher Wolf. There are currently 6 companies in Mr. Wolf’s portfolio. The largest investments include Entrada Therapeutics, Inc. and Dyne Therapeutics, together worth $118 billion.
As of 7th August 2024, Mpm Asset Management’s top holding is 4,425,784 shares of Entrada Therapeutics, Inc. currently worth over $63.1 billion and making up 34.6% of the portfolio value.
In addition, the fund holds 1,561,496 shares of Dyne Therapeutics worth $55.1 billion, whose value grew 78.0% in the past six months.
The third-largest holding is iTeos Therapeutics worth $40.6 billion and the next is Werewolf Therapeutics, Inc. worth $10.5 billion, with 4,284,172 shares owned.
Currently, Mpm Asset Management's portfolio is worth at least $182 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Mpm Asset Management office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Christopher Wolf serves as the Chief Financial Officer at Mpm Asset Management.
Christopher Wolf disclosed a decreased stake in Dyne Therapeutics by 0.5%.
This leaves the value of the investment at $55.1 billion and 1,561,496 shares.
The two most similar investment funds to Mpm Asset Management are Wfa Asset Management Corp and Soros Capital Management. They manage $182 billion and $182 billion respectively.
Mpm Asset Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 59.6% of
the total portfolio value.
The fund focuses on investments in the United States as
33.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $540 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Entrada Therapeutics, Inc. |
No change
4,425,784
|
$63,067,422,000 | 34.64% |
| Dyne Therapeutics, Inc. |
54.76%
1,561,496
|
$55,105,194,000 | 30.26% |
| iTeos Therapeutics, Inc. |
No change
2,738,785
|
$40,643,569,000 | 22.32% |
| Werewolf Therapeutics, Inc. |
No change
4,284,172
|
$10,453,380,000 | 5.74% |
| Repare Therapeutics Inc. |
No change
2,242,636
|
$7,400,699,000 | 4.06% |
| Adaptimmune Therapeutics Plc |
No change
5,555,461
|
$5,416,574,000 | 2.97% |
| No transactions found | |||
| Showing first 500 out of 6 holdings | |||